India Asthma Drugs Market Size, Share and Trends 2026 to 2035

The India asthma drugs market size was estimated at USD 2.16 billion in 2025 and is projected to be worth around USD 3.77 billion by 2035, growing at a CAGR of 5.72% from 2026 to 2035. The market in India is mainly driven by increasing air pollution, a rise in respiratory diseases, and the widespread use of affordable combination or generic treatments.

India Asthma Drugs Market Statical Scope

The market is significant due to the large number of patients, driven by pollution levels, the affordability of drugs, and the strength of generic manufacturing, along with the rapid growth of clinical trials. Urbanization and high levels of particulate matter in major cities significantly contribute to respiratory issues. Millions of people are affected by chronic obstructive pulmonary diseases and asthma, leading to a steady demand for essential maintenance medications. Local pharmaceutical companies produce low-cost inhalers and combination therapies, like budesonide and formoterol, ensuring that necessary care is accessible.

Essential respiratory medications are governed by national regulations, which ensure they are widely available while keeping costs in check. India also benefits from lower clinical trial costs and quick patient recruitment due to its diverse population, which supports global drug development. Respiratory therapies continue to be the best-selling products for local drug manufacturers, driving ongoing market growth.

India Asthma Drugs Market, By Medication, 2025 (%)

• Quick Relief Medications - The quick-relief medications segment, with a share of 37.80% in 2025, plays a crucial role in India's asthma market as it offers immediate help during sudden attacks, depends on affordable and easily available generics, and tackles acute symptom increases caused by severe local air pollution.
• Long-term Control Medications - The long-term control medications segment, with a share of 53.60% in 2025, leads India's asthma market as asthma is a chronic condition that needs daily management, urban pollution leads to ongoing airway inflammation, and changes in guidelines emphasize maintenance therapy to reduce emergency hospital visits.

India Asthma Drugs Market, By Mode of Administration, 2025 (%)

• Tablets and Capsules - The tablets and capsules segment, with a share of 28.70% in 2025, is significant in the India asthma drugs market due to a strong preference for oral medications among patients, common use of leukotriene modifiers like montelukast in children, and lower costs compared to specialized inhalers.
• Liquids - The liquids segment, with a share of 11.50% in 2025, including respules for nebulizers and oral syrups, is important in India's asthma drugs market because of high usage in vulnerable age groups, increased home healthcare adoption, and patient preferences for alternatives to inhalers.
• Inhalers - The inhaler segment, with a share of 48.40% in 2025, is dominating India's asthma drugs market as it offers targeted, fast-acting delivery of medication to the lungs, reduces systemic side effects, and is the main method for administering cost-effective combination therapies.

India Asthma Drugs Market, By Organization Type, 2025 (%)

• Public - The public segment, with a share of 36.90% in 2025, is important in the India asthma drugs market as it ensures high-volume access, supports affordability for low-income patients, and implements government-backed respiratory health programs.
• Private - The private healthcare sector, with a share of 63.10% in 2025, leads the India asthma drugs market as it promotes the commercial use of advanced combination therapies, addresses critical public supply shortages for essential inhalers, and caters to the spending of the growing urban middle class.

India Asthma Drugs Market, By Application, 2025 (%)

• Pediatric - The pediatric sector, with a share of 24.60% in 2025, plays a crucial role in the asthma drugs market in India due to increasing pollution, the high risk of developing airways, and a significant number of undiagnosed or severe childhood cases that need continuous care.
• Adults - The adult sector, with a share of 58.20% in 2025, is dominant in the asthma drugs market in India due to the high prevalence of chronic diseases, the rise in adult-onset and work-related triggers, and the ability to afford long-term combination treatments.

Competitive Landscape

The asthma drug market in India is dominated by major domestic and international companies like Cipla, Sun Pharma, and GSK, which provide a range of inhalers, combination medications, and biologics. This market is consolidated, driven by increasing pollution, urban growth, and a significant number of chronic respiratory illnesses.

• Cipla Limited leads the domestic respiratory care sector with its top inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination inhalers (like Budecort, Foracort, Seroflo) and dry powder inhalers (DPIs).
• Sun Pharmaceutical Industries Limited has a wide range of anti-asthmatics, bronchodilators, and oral leukotriene receptor antagonists (including montelukast formulations).
• GlaxoSmithKline Pharmaceuticals Ltd. (GSK) is a global leader with innovative maintenance inhalers (such as Fluticasone and Salmeterol combinations) and specialized therapies for severe asthma.
• Lupin Limited boasts a strong local portfolio with generic and specialized respiratory inhalers, metered-dose inhalers (MDIs), and anti-inflammatory agents.
• Dr. Reddy's Laboratories and Glenmark Pharmaceuticals provide affordable generic respiratory options, combination bronchodilators, and anti-allergic maintenance treatments.

Segments Covered in the Report

By Medication

• Long-term Control Medications
• Quick Relief Medications
• Others

By Mode of Administration

• Inhalers
• Tablets and Capsules
• Liquids
• Injections

By Organization Type

• Public
• Private
• By Application
• Adults
• Pediatric
  
• Adolescent